Global Health Highlights: Innovations, Outbreaks, and Pharmaceutical Progress

Recent developments in global health feature the U.S. FDA exploring drug repurposing, H. Lundbeck's optimistic forecast buoyed by U.S. demand, and a concerning hantavirus outbreak affecting cruise passengers. Also in focus is Roche’s latest Alzheimer’s test approval, a strategic acquisition by Cellular Intelligence, and ongoing discussions about essential medicine shortages in the EU.

In recent health news, the U.S. FDA has announced plans to seek input on repurposing approved drugs, potentially broadening their use across various diseases. Meanwhile, Danish pharmaceutical company H. Lundbeck has adjusted its 2026 sales forecasts due to strong demand in the U.S. and postponed generic competition.

The hantavirus outbreak remains a concern with 18 passengers repatriated and monitored in the U.S., following an incident aboard a luxury cruise ship. This development comes alongside Germany's decision to isolate contacts from the same cruise as precautionary measures.

Further, advancements continue as Roche secures a second European approval for its Alzheimer's blood test, developed in collaboration with Eli Lilly. Moreover, there's rising interest as Cellular Intelligence, backed by Mark Zuckerberg, acquires a cell therapy for Parkinson's from Novo Nordisk. EU efforts to combat medicine shortages also underscore the need for strategic planning in the pharmaceutical sector.